USPTO Examiner AUDET MAURY A - Art Unit 1654

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18883317LONG-ACTING AMYLIN RECEPTOR AGONISTS AND USES THEREOFSeptember 2024October 2025Allow1300YesNo
18496636INJECTION PEN FOR SUBCUTANEOUS ADMINISTRATION OF A PEPTIDEOctober 2023March 2025Allow1721YesNo
18486390COMPOSITIONS AND METHODS FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASEOctober 2023March 2025Abandon1710NoNo
18378229Charged Nutritive Proteins and MethodsOctober 2023June 2025Abandon2010NoNo
18368347LONG-ACTING PARATHYROID HORMONESeptember 2023October 2024Allow1322YesNo
18451467GENERATING A MICROEMULSION FORMATION WITH IMPROVED SOLUBILITYAugust 2023May 2025Abandon2121YesNo
18229793COMBINATION OF AN INSULIN AND A GLP-1-AGONISTAugust 2023July 2025Abandon2420NoNo
18362578NOVEL ANGIOTENSIN I-CONVERTING ENZYME (ACE) INHIBITORY PEPTIDESJuly 2023January 2025Allow1710YesNo
18296104PHARMACEUTICAL COMBINATIONS FOR TREATING CANCERApril 2023March 2025Abandon2410NoNo
18116766PARATHYROID HORMONE VARIANTSMarch 2023January 2025Allow2210YesNo
18109096PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS AND USES THEREOFFebruary 2023February 2026Abandon3610NoNo
18167260NASAL POWDER FORMULATION FOR TREATMENT OF HYPOGLYCEMIAFebruary 2023March 2025Allow2510YesNo
18102933PORCINE G-CSF VARIANTS AND THEIR USESJanuary 2023December 2024Allow2310YesNo
18146946PHARMACEUTICAL COMPOSITION FOR TREATING RETINAL DYSTROPHIES, COMPRISING NKX3.2 AND FRAGMENT THEREOF AS ACTIVE INGREDIENTSDecember 2022December 2024Abandon2420NoNo
17985271STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ANALOGUES AND/OR INSULIN DERIVATIVESNovember 2022December 2024Abandon2610NoNo
17961220TRIPLE G-C-T BASE CODED NUCLEOBASE AMINO ACID, ITS SYNTHESIS AND PEPTIDE FORMATIONOctober 2022September 2025Allow3511YesNo
17937041COMPOSITIONS AND METHODS FOR BIOORTHOGONAL SURFACE COATINGSeptember 2022July 2025Allow3311YesNo
17933471OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASESeptember 2022October 2025Allow3730YesNo
17946098BRAIN FUNCTION REGULATING AGENT, AND FOOD OR BEVERAGE PRODUCT CONTAINING SAMESeptember 2022October 2025Allow3740YesNo
17864645STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ANALOGUES AND/OR INSULIN DERIVATIVESJuly 2022October 2024Abandon2710NoNo
17854918RECOMBINANT PROTEIN COMPRISING MULTIPLE MULTI-PEPTIDE SETS, PHARMACEUTICAL COMPOSITION COMPRISING THE RECOMBINANT PROTEIN, AND METHOD FOR PREPARING THE RECOMBINANT PROTEINJune 2022September 2025Allow3822YesNo
17664040PHARMACEUTICAL COMPOSITION, USE AND METHOD FOR APPLYING GANODERMA MICROSPORUM IMMUNOMODULATORY PROTEIN AND KEYHOLE LIMPET HEMOCYANIN IN CARCINOMA TREATMENTMay 2022January 2026Abandon4410NoNo
17740001NITROXYLATED PROTEINS AND METHODS FOR THE USE THEREOFMay 2022September 2024Abandon2810NoNo
17729502C-TERMINAL FRAGMENT OF TETANUS TOXIN (HC) FOR TREATMENT OF DEPRESSIONApril 2022August 2024Allow2810NoNo
17657885ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOFApril 2022April 2025Allow3640YesNo
17700836TREATMENT AND PREVENTION OF CARDIORENAL DAMAGEMarch 2022June 2024Abandon2740NoNo
17695071SERUM AMYLOID P DERIVATIVES AND THEIR PREPARATION AND USEMarch 2022May 2024Abandon2610NoNo
17691610PROTEINS FOR THE TREATMENT OF EPITHELIAL BARRIER FUNCTION DISORDERSMarch 2022August 2024Allow3010NoNo
17641264ANTI-VIRAL COMPOSITIONS AND METHODS OF MAKING AND USINGMarch 2022September 2025Allow4200YesNo
17687864NOVEL FORMULATIONSMarch 2022July 2024Abandon2810NoNo
17684578LONG ACTING AMYLIN RECEPTOR AGONISTS AND USES THEREOFMarch 2022June 2024Allow2730NoNo
17638040PBP BINDING BICYCLIC PEPTIDE LIGANDSFebruary 2022March 2026Abandon4811NoNo
17635990POLYPEPTIDE AND USE THEREOFFebruary 2022June 2025Allow4010YesNo
17633200A METHOD FOR MODIFICATION OF PEPTIDES IMMOBILIZED ON A SOLID SUPPORT BY TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULESFebruary 2022October 2025Allow4431YesNo
17665360METHODS OF TREATING MILD BRAIN INJURYFebruary 2022March 2025Allow3710YesNo
17590875HETEROTANDEM BICYCLIC PEPTIDE COMPLEXESFebruary 2022November 2025Allow4521YesNo
17587311COMPOSITIONS AND METHODS FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASEJanuary 2022January 2024Abandon2420NoNo
17630314BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2January 2022October 2025Allow4521YesNo
17583883METHODS AND COMPOSITIONS FOR TREATING MUSCLE DISEASE AND DISORDERSJanuary 2022December 2024Abandon3531YesNo
17582999METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILUREJanuary 2022October 2024Abandon3301NoNo
17577930CHIMERIC TIM-3 FUSION PROTEINJanuary 2022July 2024Abandon3001NoNo
17576821Derivatisation of Insulin with PolysaccharidesJanuary 2022February 2025Abandon3720NoNo
17618781A Manufacturing Process for Peptide and Protein ProductionDecember 2021May 2025Abandon4112YesNo
17548204TARGETED ANTICOAGULANTDecember 2021December 2024Abandon3720NoNo
17512298GLYCOPEPTIDE ANTIBIOTICS LIQUID FORMULATIONS AND METHODS AND USES THEREOFOctober 2021April 2024Allow3041YesNo
17491067MODIFIED PEPTIDESSeptember 2021January 2025Abandon4021NoNo
17486432METHOD AND COMPOSITIONS COMPRISING A CT20 PEPTIDESeptember 2021August 2024Allow3520NoNo
17486551Method to Identify Responders to Osteoarthritis TherapeuticsSeptember 2021September 2025Allow4771YesNo
17485345USE OF CHELATING AGENT AND PEPTIDE ANTIMICROBIAL COMPOUNDSSeptember 2021March 2025Allow6030YesNo
17483934PEPTIDE INHIBITORS OF TIGHT JUNCTION PERMEABILITYSeptember 2021March 2024Abandon3010NoNo
17481490METHOD TO INHIBIT NEUTROPHIL RECRUITMENT TO DAMAGED TISSUE USING MYELOID-DERIVED GROWTH FACTORSeptember 2021January 2024Allow2730NoNo
17440916METHOD OF TREATING INFECTIVE ENDOCARDITISSeptember 2021September 2024Abandon3601NoNo
17403278Methods for Measuring Consumption of Amino Acid N-Carboxyanhydrides during Manufacture of Glatiramer AcetateAugust 2021April 2024Abandon3201NoNo
17394522SOLUBLE NPY2 RECEPTOR AGONISTSAugust 2021January 2025Allow4121YesNo
17391805PROTEIN INHIBITORS WITH REDUCED IMMUNOGENICITY AND RESISTANCE TO DEGRADATION, AND METHODS FOR THEIR PREPARATION AND USEAugust 2021July 2023Allow2320YesNo
17367339STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ASPARTJuly 2021December 2023Abandon3010NoNo
17367340STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ANALOGUES AND/OR INSULIN DERIVATIVESJuly 2021December 2023Abandon3010NoNo
17366998GIP/GLP1 CO-AGONIST COMPOUNDSJuly 2021June 2024Allow3621YesNo
17364162METHOD FOR DETECTING CANCER CELLS, REAGENT FOR INTRODUCING SUBSTANCE INTO CANCER CELLS, AND COMPOSITION FOR TREATING CANCERJune 2021December 2023Abandon3010NoNo
17357374Hemoglobin Derivative Co-conjugated with Fatty Acid-linked PEG and Alkoxy PEG as a Blood SubstituteJune 2021March 2025Allow4540YesNo
17353965S-LAYER VACCINE FUSION PROTEINS AND METHODS OF USEJune 2021September 2024Abandon3912NoNo
17299945PHARMACEUTICAL COMPOSITION, COMPRISING INHIBITORY PEPTIDE AGAINST FAS SIGNALING, FOR PREVENTION OR TREATMENT OF OBESITY, FATTY LIVER, OR STEATOHEPATITISJune 2021August 2024Abandon3801NoNo
17299745LINEAR SOLUTION PHASE ROUTES FOR WNT HEXAPEPTIDESJune 2021August 2024Allow3820NoNo
17302831HUMAN PLACENTAL COLLAGEN COMPOSITIONS AND METHODS OF MAKING AND USING THE SAMEMay 2021October 2023Abandon2910NoNo
17315020METHOD FOR PREVENTING OR TREATING OSTEOPOROSIS, CHARACTERIZED BY ADMINISTERING TERIPARATIDE OR SALT THEREOF AT A FREQUENCY OF TWICE A WEEKMay 2021October 2022Allow1730YesNo
17244214METHOD AND COMPOSITIONS FOR THE TREATMENT AND DETECTION OF ENDOTHELIN-1 RELATED KIDNEY DISEASESApril 2021November 2023Allow3130YesNo
17290109METHOD FOR MODIFICATION OF POLYPETIDE AND USESApril 2021December 2023Abandon3240YesNo
17239433PHARMACEUTICAL COMPOSITION COMPRISING RUNX3 PROTEIN AND CDK4 INHIBITOR OR mTOR INHIBITOR COTREATMENT FOR PREVENTION OR TREATMENT OF CANCERApril 2021May 2025Allow4940YesNo
17287581NEUROLOGICAL DISEASE TREATMENT WITH ZILUCOPLANApril 2021October 2024Abandon4240YesNo
17237632COMBINATION OF AN INSULIN AND A GLP-1-AGONISTApril 2021September 2023Abandon2910NoNo
17220177ANTI-BACTERIAL CALCIUM-DEPENDENT ANTIBIOTIC (CDA) ANALOGS AND METHODS OF TREATING BACTERIAL INFECTIONSApril 2021April 2024Abandon3630NoNo
17274705BRAIN FUNCTION REGULATING AGENT, AND FOOD OR BEVERAGE PRODUCT CONTAINING SAMEMarch 2021December 2022Abandon2220NoNo
17273546PHARMACEUTICAL COMPOSITION FOR TREATING RETINAL DYSTROPHIES, COMPRISING NKX3.2 AND FRAGMENT THEREOF AS ACTIVE INGREDIENTSMarch 2021December 2022Allow2210YesNo
17177665METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITORFebruary 2021April 2024Abandon3810NoYes
17176983CYCLIC PEPTIDE FOR TREATING CANCERFebruary 2021April 2024Allow3820YesNo
17176442Long-Acting Formulations of InsulinFebruary 2021September 2025Abandon5550YesNo
17169833PROTEASE-RESISTANT LIPIDATED GLP-1 ANALOGSFebruary 2021December 2022Abandon2310NoNo
17265165DUAL AGONIST FUSION PROTEINSFebruary 2021January 2023Allow2320YesNo
17157130RECOMBINANT PROTHROMBIN ANALOGUES AND USES THEREOFJanuary 2021February 2024Allow3620NoNo
17261822METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASES USING FAT SPECIFIC PROTEIN 27 (FSP27) COMPOSITIONSJanuary 2021February 2023Abandon2521NoNo
17149830Mutated Immunoglobulin-Binding PolypeptidesJanuary 2021October 2024Allow4531YesNo
17145231PROTEIN PURIFICATIONJanuary 2021May 2023Allow2910YesNo
17145235PROTEIN PURIFICATIONJanuary 2021May 2023Allow2810YesNo
17145233PROTEIN PURIFICATIONJanuary 2021June 2023Allow3010YesNo
17140449Self-Assembling Collagen-Like Polypeptides for Applications and Uses Related TheretoJanuary 2021December 2024Allow4730YesYes
17134977Peptides and Nanoparticle Formulations ThereofDecember 2020March 2024Allow3930YesNo
17128632ASTEXIN PEPTIDESDecember 2020April 2023Allow2710NoNo
17124572METHODS FOR TREATING ALOPECIA AND ACHROMOTRICHIADecember 2020March 2023Abandon2710NoNo
17118521TISSUE CATALYZED GROWTH OF POLYMER AS EPITHELIAL LININGS FOR THERAPYDecember 2020February 2024Allow3821YesNo
17116054ANTIMICROBIAL COMPOUNDSDecember 2020September 2022Allow2111NoNo
16972381HYPERTROPHIC SCAR INHIBITING COMPOSITIONDecember 2020December 2022Abandon2540NoNo
17109056NOVEL ANGIOTENSIN I-CONVERTING ENZYME (ACE) INHIBITORY PEPTIDESDecember 2020April 2023Allow2920YesNo
17104734METHOD FOR PREVENTING OR TREATING OSTEOPOROSIS, CHARACTERIZED BY ADMINISTERING TERIPARATIDE OR SALT THEREOF AT A FREQUENCY OF TWICE A WEEKNovember 2020September 2021Abandon1010NoNo
17095992PCSK9 INHIBITORY POLYPOLYPEPTIDES AND METHODS OF USENovember 2020October 2022Allow6020YesNo
17054740METHODS AND COMPOSITIONS FOR TREATING DECREASED COGNITIVE ABILITYNovember 2020January 2024Allow3930YesNo
17094175METHOD AND COMPOSITIONS FOR THE TREATMENT AND DETECTION OF ENDOTHELIN-1 RELATED KIDNEY DISEASESNovember 2020March 2022Allow1610YesNo
17086188COMPOSITIONS AND METHODS FOR TREATING EYE INFECTIONS AND DISEASEOctober 2020December 2023Abandon3840NoNo
17069443PHARMACEUTICAL COMPOSITION, USE AND METHOD FOR APPLYING GANODERMA MICROSPORUM IMMUNOMODULATORY PROTEIN AND KEYHOLE LIMPET HEMOCYANIN IN CARCINOMA TREATMENTOctober 2020December 2022Abandon2740YesNo
17069558ARTIFICIAL TRANSCRIPTION FACTORS COMPRISING A SLIDING DOMAIN AND USES THEREOFOctober 2020August 2024Allow4630YesNo
17068849TREATMENT OF INFLAMMATIONOctober 2020June 2024Allow4460NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner AUDET, MAURY A.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
3
Examiner Affirmed
2
(66.7%)
Examiner Reversed
1
(33.3%)
Reversal Percentile
49.4%
Lower than average

What This Means

With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
102
Allowed After Appeal Filing
21
(20.6%)
Not Allowed After Appeal Filing
81
(79.4%)
Filing Benefit Percentile
27.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 20.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner AUDET, MAURY A - Prosecution Strategy Guide

Executive Summary

Examiner AUDET, MAURY A works in Art Unit 1654 and has examined 952 patent applications in our dataset. With an allowance rate of 53.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.

Allowance Patterns

Examiner AUDET, MAURY A's allowance rate of 53.4% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by AUDET, MAURY A receive 2.13 office actions before reaching final disposition. This places the examiner in the 57% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by AUDET, MAURY A is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +21.0% benefit to allowance rate for applications examined by AUDET, MAURY A. This interview benefit is in the 65% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 13.9% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 40.2% of cases where such amendments are filed. This entry rate is in the 62% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 133.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 85% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 94.3% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 88.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 69.8% are granted (fully or in part). This grant rate is in the 77% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 20.6% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.8% of allowed cases (in the 72% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.